SESSION TITLE: Interstitial Lung Disease Case Report Posters
SESSION TYPE: Affiliate Case Report Poster
PRESENTED ON: Tuesday, October 28, 2014 at 01:30 PM - 02:30 PM
INTRODUCTION: Melphalan induced interstitial pneumonitis is rare. With the increased use of high dose melphalan prior to autologous hematopoietic cell transplantation, it is prudent to consider this in the differential diagnosis of post-transplant respiratory failure. We present an interesting case of melphalan induced pulmonary toxicity with excellent response to corticosteroids.
CASE PRESENTATION: A 55 year-old female was diagnosed with IgA lambda Multiple Myeloma and treated with bortezomib, revlimid, and dexamethasone for about 5 years. Nevertheless progressive disease necessitated high dose melphalan followed by autologous hematopoietic progenitor cell transplant. Four weeks post-transplantation, she presented with hypoxic respiratory failure. Broad spectrum antibiotics including coverage for Pneumocystis jiroveci were initiated. Computerized tomography imaging showed multiple bilateral patchy centrilobular groundglass and mosaic attenuation. Respiratory failure ensued despite antimicrobial therapy requiring intubation and mechanical ventilation. A bronchoscopy with bronchoalveolar lavage (BAL) showed 213 leucocytes with 52% lymphocytes. BAL cultures, fungal and viral serologies were negative. As differential narrowed to non-infectious etiologies, melphalan induced pulmonary toxicity was considered. With significant BAL lymphocytosis, intravenous corticosteroids were initiated and tapered to oral prednisone. A dramatic improvement in oxygen requirements was observed from 60% high flow to 2 L/min at discharge. After 3 months, the patient’s lung function returned to baseline. She has been weaned off oxygen and has excellent functional status.
DISCUSSION: Melphalan is well known for extra-medullary toxicity like mucositis and diarrhea. Lung toxicity has been seldom reported.1 Bilateral groundglass opacities, developing about 4-6 weeks after high dose melphalan therapy should raise suspicion for pulmonary toxicity. Early initiation of corticosteroids proved beneficial in our patient as well as in another report1. Exact role of corticosteroids in therapy of melphalan lung toxicity is unknown.
CONCLUSIONS: Melphalan induced interstitial pneumonitis should be considered in patients with hematopoietic cell transplantation. Early initiation of corticosteroids after ruling out infection may facilitate radiographic and clinical recovery.
Reference #1: Akasheh, et al. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26:1107-09.
DISCLOSURE: The following authors have nothing to disclose: Tanmay Panchabhai, Debabrata Bandyopadhyay, Pradnya Patil, Umur Hatipoglu
No Product/Research Disclosure Information